ANTX - AN2 Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ANTX is currently covered by 6 analysts with an average price target of $5.12. This is a potential upside of $3.83 (296.9%) from yesterday's end of day stock price of $1.29.

AN2 Therapeutics's activity chart (see below) currently has 10 price targets and 27 ratings on display. The stock rating distribution of ANTX is 55% BUY and 45% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 29.17% with an average time for these price targets to be met of 69 days.

Highest price target for ANTX is $5, Lowest price target is $1, average price target is $11.

Most recent stock forecast was given by ROY BUCHANAN from JMP on 26-Mar-2025. First documented stock forecast 19-Apr-2022.

Best performing analysts who are covering ANTX - AN2 Therapeutics:

Kevin Degeeter Joseph Schwartz Liisa Bayko Roy Buchanan

Currently out of the existing stock ratings of ANTX, 11 are a BUY (55%), 9 are a HOLD (45%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$5

$3.74 (296.83%)

$5

30 days ago
(26-Mar-2025)

0/7 (0%)

$3.48 (228.95%)

Hold

$1

$-0.26 (-20.63%)

8 months 16 days ago
(09-Aug-2024)

1/3 (33.33%)

$-0.03 (-2.91%)

7

$2

8 months 16 days ago
(09-Aug-2024)

1/3 (33.33%)

$-0.27 (-11.89%)

15

Buy

$27

$25.74 (2042.86%)

$24

1 years 7 months 12 days ago
(13-Sep-2023)

2/4 (50%)

$12.12 (81.45%)

254

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ANTX (AN2 Therapeutics) average time for price targets to be met?

On average it took 69 days on average for the stock forecasts to be realized with a an average price target met ratio 29.17

Which analyst has the current highest performing score on ANTX (AN2 Therapeutics) with a proven track record?

KEVIN DEGEETER

Which analyst has the current lower performing score on ANTX (AN2 Therapeutics) with a proven track record?

ROY BUCHANAN

Which analyst has the most public recommendations on ANTX (AN2 Therapeutics)?

Kevin Degeeter has 4 price targets and 3 ratings on ANTX

Which analyst is the currently most bullish on ANTX (AN2 Therapeutics)?

Kevin Degeeter with highest potential upside - $25.74

Which analyst is the currently most reserved on ANTX (AN2 Therapeutics)?

Joseph Schwartz with lowest potential downside - -$0.26

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?